Neoadjuvant Chemotherapy or Endocrine Therapy for Strongly HR-Positive, ERBB2-Negative Invasive Ductal Carcinoma of the Breast
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
JAMA Netw Open 2021 Mar 01;4(3)e211785, J Zhang, CY Lu, HM Chen, SY WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.